Valacyclovir is indicated for the treatment of cold sores (herpes labialis), genital herpes, reduction of transmission of genital herpes, shingles (herpes zoster, and suppression therapy for herpes. Valacyclovir hydrochloride (the L-valyl ester prodrug of acyclovir) is a nucleoside analogue DNA polymerase inhibitor. After conversion to acyclovir, the drug binds selectively to thymidine kinase (encoded by herpes simplex virus and varicella-zoster virus) and converts to acyclovir monophosphate. After conversion ultimately to a triphosphate form, acyclovir triphosphate stops replication of herpes viral DNA through competitive inhibition and inactivation of viral DNA polymerase and incorporation and termination of the growing viral DNA chain
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.